Literature DB >> 19082771

The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus.

Zu-Bing Chen1, Shi-Qiang Shen, You-Ming Ding, Wei-Xing Wang, Jian-Ping Tao, Li-Jian Liang, Wen-Jie Hu.   

Abstract

The objective of this study was to investigate the expressions of angiogenic factors and elucidate their angiogenic and prognostic roles in hepatocellular carcinoma (HCC) with background of hepatitis B virus (HBV). We evaluated microvessel density (MVD) of HCC, and investigated immunohistochemical expression of vascular endothelial growth factor (VEGF), angiopoietins (Ang-1 and Ang-2), and matrix metalloproteinases-9 (MMP-9) in 67 specimens of surgically resected HCC, which were all positive for hepatitis B surface antigen. We investigated the relationship between their expressions and clinicopathological factors or prognosis. The microvessel density (MVD) of tumor tissue and surrounding normal liver tissue was 93.1 +/- 43.8/mm2 and 30.4 +/- 14.8/mm2, respectively. The MVD of well-differentiated HCC was significantly less than that of poorly differentiated HCC. MVD was positively correlated with VEGF and Ang-2 expression (P = 0.0023 and 0.0265, respectively). There was less tumor recurrence in low Ang-2 and low MMP-9 group than high Ang-2 and/or high MMP-9 group (P = 0.002). In Cox regression model, portal vein thrombus and intrahepatic metastasis was the risk factors of tumor recurrence (P = 0.003 and 0.001, respectively). Our study showed that the expression of VEGF and Ang-2 were positively correlated with MVD. Ang-2 expression and/or MMP-9 expression might be a significant predictive factor for recurrence after resection in HCC patients with the background of HBV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19082771     DOI: 10.1007/s12032-008-9130-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients.

Authors:  Pampee P Young; A Alex Hofling; Mark S Sands
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

2.  Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha.

Authors:  Hiroshi Wada; Hiroaki Nagano; Hirofumi Yamamoto; Yubo Yang; Motoi Kondo; Hideo Ota; Masato Nakamura; Shinichi Yoshioka; Hitoshi Kato; Bazarragchaa Damdinsuren; Di Tang; Sigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Shoji Nakamori; Masato Sakon; Keizo Dono; Kenichi Wakasa; Morito Monden
Journal:  Liver Int       Date:  2006-05       Impact factor: 5.828

3.  Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.

Authors:  Hitoshi Yoshiji; Shigeki Kuriyama; Junichi Yoshii; Yasuhide Ikenaka; Ryuichi Noguchi; Daniel J Hicklin; James Huber; Toshiya Nakatani; Hirohisa Tsujinoue; Koji Yanase; Hiroo Imazu; Hiroshi Fukui
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

4.  Microvessel density of hepatocellular carcinoma: its relationship with prognosis.

Authors:  H C Sun; Z Y Tang; X M Li; Y N Zhou; B R Sun; Z C Ma
Journal:  J Cancer Res Clin Oncol       Date:  1999-07       Impact factor: 4.553

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma.

Authors:  R T Poon; I O Ng; C Lau; W C Yu; S T Fan; J Wong
Journal:  Am J Surg       Date:  2001-09       Impact factor: 2.565

7.  Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.

Authors:  O N El-Assal; A Yamanoi; Y Soda; M Yamaguchi; M Igarashi; A Yamamoto; T Nabika; N Nagasue
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

8.  Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

Authors:  Junji Furuse; Hiroshi Ishii; Kohei Nakachi; Eiichiro Suzuki; Satoshi Shimizu; Keiko Nakajima
Journal:  Cancer Sci       Date:  2007-10-22       Impact factor: 6.716

9.  Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.

Authors:  H Yoshiji; S Kuriyama; J Yoshii; Y Ikenaka; R Noguchi; D J Hicklin; Y Wu; K Yanase; T Namisaki; M Yamazaki; H Tsujinoue; H Imazu; T Masaki; H Fukui
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

10.  A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma.

Authors:  Y Ishii; Y Nakasato; S Kobayashi; Y Yamazaki; T Aoki
Journal:  J Exp Clin Cancer Res       Date:  2003-09
View more
  11 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.

Authors:  Pengyuan Yang; Geoffrey J Markowitz; Xiao-Fan Wang
Journal:  Natl Sci Rev       Date:  2014-07-14       Impact factor: 17.275

3.  Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma.

Authors:  Qi-Kai Sun; Jian-Yu Zhu; Wei Wang; Yang Lv; Hang-Cheng Zhou; Ji-Hai Yu; Ge-Liang Xu; Jin-Liang Ma; Wen Zhong; Wei-Dong Jia
Journal:  Med Oncol       Date:  2013-12-03       Impact factor: 3.064

4.  Intracellular pathogen Leishmania donovani activates hypoxia inducible factor-1 by dual mechanism for survival advantage within macrophage.

Authors:  Amit Kumar Singh; Chaitali Mukhopadhyay; Sudipta Biswas; Vandana Kumari Singh; Chinmay K Mukhopadhyay
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

5.  Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Jeffrey S Morris; Michiko Iwasaki; Humaid O Al-Shamsi; Kanwal Pratap Singh Raghav; Lauren Girard; Sheree Cheung; Van Nguyen; Khaled M Elsayes; Lianchun Xiao; Reham Abdel-Wahab; Ahmed S Shalaby; Manal Hassan; Hesham M Hassabo; Robert A Wolff; James C Yao
Journal:  Onco Targets Ther       Date:  2016-02-15       Impact factor: 4.147

6.  Expression of Angiopoietin and VEGF in Cervical Cancer and its Clinical Significance.

Authors:  Qingyuan Lv; Weijuan Zhong; Xiabin Ye; Yang Lv; Haiying Liu; Guizhen Yan; Diwen Chen
Journal:  Open Life Sci       Date:  2018-12-31       Impact factor: 0.938

7.  Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma.

Authors:  Soon Ha Kwon; Soung Won Jeong; Jae Young Jang; Ji Eun Lee; Sae Hwan Lee; Sang Gyune Kim; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; So-Young Jin
Journal:  Clin Mol Hepatol       Date:  2012-09-25

Review 8.  VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications.

Authors:  Khaled R Alkharsah
Journal:  Int J Mol Sci       Date:  2018-06-01       Impact factor: 5.923

9.  Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas.

Authors:  Su-Min Ha; Shin Hwang; Jin Young Park; Young-Joo Lee; Ki-Hun Kim; Gi-Won Song; Dong-Hwan Jung; Yun-Suk Yu; Jinpyo Kim; Kyoung-Jin Lee; Eunyoung Tak; Yo-Han Park; Sung-Gyu Lee
Journal:  Ann Surg Treat Res       Date:  2018-11-26       Impact factor: 1.859

Review 10.  The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma.

Authors:  Bart Vanderborght; Sander Lefere; Hans Van Vlierberghe; Lindsey Devisscher
Journal:  Cells       Date:  2020-10-30       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.